FI963334L - Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö - Google Patents
Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö Download PDFInfo
- Publication number
- FI963334L FI963334L FI963334A FI963334A FI963334L FI 963334 L FI963334 L FI 963334L FI 963334 A FI963334 A FI 963334A FI 963334 A FI963334 A FI 963334A FI 963334 L FI963334 L FI 963334L
- Authority
- FI
- Finland
- Prior art keywords
- tyrosinase
- peptides derived
- isolated peptides
- isolated
- derived
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/203,054 US5530096A (en) | 1992-12-22 | 1994-02-28 | Isolated, tyrosinase derived peptides and uses thereof |
| US08/233,305 US5519117A (en) | 1992-12-22 | 1994-04-26 | Isolated, tyrosinase derived peptides and uses thereof |
| PCT/US1995/001990 WO1995023234A1 (en) | 1994-02-28 | 1995-02-16 | Isolated, tyrosinase derived peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI963334A0 FI963334A0 (fi) | 1996-08-27 |
| FI963334L true FI963334L (fi) | 1996-08-27 |
| FI963334A7 FI963334A7 (fi) | 1996-08-27 |
Family
ID=26898269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI963334A FI963334A7 (fi) | 1994-02-28 | 1995-02-16 | Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5519117A (fi) |
| EP (1) | EP0750679A4 (fi) |
| JP (1) | JP3721437B2 (fi) |
| CN (1) | CN1169966C (fi) |
| AU (1) | AU677766B2 (fi) |
| CA (1) | CA2184175C (fi) |
| FI (1) | FI963334A7 (fi) |
| NO (1) | NO963487L (fi) |
| NZ (1) | NZ282528A (fi) |
| WO (1) | WO1995023234A1 (fi) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
| PT1025849E (pt) | 1992-12-22 | 2002-09-30 | Ludwig Inst Cancer Res | Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase |
| US5851523A (en) * | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
| US5997870A (en) * | 1994-06-03 | 1999-12-07 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B44 Molecules |
| US5589334A (en) * | 1994-06-03 | 1996-12-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof |
| US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
| US7501501B2 (en) | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| US6096313A (en) * | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US6680191B1 (en) | 1997-04-25 | 2004-01-20 | Ludwig Institute For Cancer | Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof |
| US6667037B1 (en) * | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
| EP1227837B1 (en) | 1999-10-22 | 2008-05-21 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| ATE494387T1 (de) * | 2001-11-07 | 2011-01-15 | Mannkind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898814A (en) * | 1986-10-06 | 1990-02-06 | Donald Guthrie Foundation For Medical Research, Inc. | A cDNA clone for human tyrosinase |
| PT1025849E (pt) * | 1992-12-22 | 2002-09-30 | Ludwig Inst Cancer Res | Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase |
-
1994
- 1994-04-26 US US08/233,305 patent/US5519117A/en not_active Expired - Lifetime
-
1995
- 1995-02-16 EP EP19950912563 patent/EP0750679A4/en not_active Withdrawn
- 1995-02-16 WO PCT/US1995/001990 patent/WO1995023234A1/en not_active Ceased
- 1995-02-16 JP JP52239095A patent/JP3721437B2/ja not_active Expired - Lifetime
- 1995-02-16 NZ NZ282528A patent/NZ282528A/en unknown
- 1995-02-16 AU AU19668/95A patent/AU677766B2/en not_active Expired
- 1995-02-16 CA CA002184175A patent/CA2184175C/en not_active Expired - Lifetime
- 1995-02-16 CN CNB951918559A patent/CN1169966C/zh not_active Expired - Lifetime
- 1995-02-16 FI FI963334A patent/FI963334A7/fi unknown
- 1995-10-19 US US08/545,212 patent/US5843687A/en not_active Expired - Lifetime
-
1996
- 1996-08-22 NO NO963487A patent/NO963487L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI963334A0 (fi) | 1996-08-27 |
| AU677766B2 (en) | 1997-05-01 |
| CN1169966C (zh) | 2004-10-06 |
| NO963487D0 (no) | 1996-08-22 |
| CN1154144A (zh) | 1997-07-09 |
| NO963487L (no) | 1996-08-28 |
| WO1995023234A1 (en) | 1995-08-31 |
| JP3721437B2 (ja) | 2005-11-30 |
| JPH09509325A (ja) | 1997-09-22 |
| EP0750679A4 (en) | 1997-06-11 |
| US5843687A (en) | 1998-12-01 |
| NZ282528A (en) | 1998-05-27 |
| FI963334A7 (fi) | 1996-08-27 |
| AU1966895A (en) | 1995-09-11 |
| CA2184175A1 (en) | 1995-08-31 |
| US5519117A (en) | 1996-05-21 |
| HK1001404A1 (en) | 1998-06-19 |
| CA2184175C (en) | 2007-04-17 |
| EP0750679A1 (en) | 1997-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI965225A7 (fi) | Uusia peptidejä | |
| FI961350L (fi) | Hapteenimerkityt peptidit | |
| BR9607317A (pt) | Peptídios e composição farmacêutica | |
| BR9607318A (pt) | Peptidos e composição farmacêutica | |
| DE69625368D1 (de) | Schweisshemmende deodorierende präparaten | |
| DK0921796T3 (da) | Tetrahydrolipstatinholdige præparater | |
| FI963065A7 (fi) | Kaksikerroksiset valmisteet | |
| ATE328083T1 (de) | Menschlicher bikunin | |
| BR9506832A (pt) | N-pirazolilanilinas e n-pirazolilaminopiridinas | |
| NO985680L (no) | Peptidderivater | |
| IS4459A (is) | Ný peptíð er hafa ónæmisbreytandi áhrif | |
| FI963334L (fi) | Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö | |
| DE59707298D1 (de) | Desodorierende zubereitungen | |
| NO983849D0 (no) | Peptidderivater | |
| FI970168A0 (fi) | Peptidejä | |
| FI964363L (fi) | Peptidejä | |
| DK0826679T3 (da) | Naphthylforbindelser og -præparater | |
| TR199701666A3 (tr) | Sismanliga karsi proteinler | |
| KR960010685A (ko) | 펩티드 및 그 용도 | |
| FI972965A7 (fi) | Uusia peptidejä, niiden valmistus ja käyttö | |
| PT950063E (pt) | Construcoes peptidicas multirramificadas | |
| NO981052D0 (no) | Peptidderivater | |
| NO981051D0 (no) | Peptidderivater | |
| DE69523817D1 (de) | Desodorisierende Präparate | |
| DE69434900D1 (de) | Menschliche chemokin-polypeptide |